Sight Sciences, Inc., (SGHT) News
Filter SGHT News Items
SGHT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SGHT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SGHT News From Around the Web
Below are the latest news stories about SIGHT SCIENCES INC that investors may wish to consider to help them evaluate SGHT as an investment opportunity.
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle GlaucomaThe study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates sustained intraocular pressure reductions and decreased medication dependenceMENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, i |
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment OptionsBudget impact analysis published in the Expert Review of Ophthalmology journalMENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis (“BIA”) of the TearCare® System (“TearCare”) for the treatment of MGD-associated dry eye di |
Sight Sciences initiated with a Buy at UBSUBS initiated coverage of Sight Sciences (SGHT) with a Buy rating and $5.50 price target After a tough 2024, 2025 represents a “foundational building year” in which the company’s key growth driver will shift away from the legacy Omni surgical solution to treat glaucoma and to the TearCare dry eye solution, the analyst tells investors in a research note. The firm says TearCare addresses more than 11M patients with meibomian gland disease with an addressable market of $2.5B. Published first on The |
Nano Dimension Leads 3 US Penny Stocks To ConsiderAs the Dow Jones and S&P 500 reach new highs, investors are increasingly looking for opportunities beyond the traditional large-cap stocks. Penny stocks, though often considered a relic of past trading days, still hold potential for those willing to explore smaller or newer companies with solid financial foundations. These stocks can offer a unique blend of affordability and growth potential, making them an intriguing option for investors seeking hidden value in today's market landscape. |
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare ConferenceMENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm E |
Inside a $400 billion bet on the brain-computer interface revolutionMorgan Stanley's latest report pegs the BCI market at $400 billion — signaling to investors that this revolutionary technology is the next big bet in medtech. |
Sight Sciences price target lowered to $5 from $7 at Morgan StanleyMorgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Sight Sciences (SGHT) to $5 from $7 and keeps an Equal Weight rating on the shares. Along with Q3 results, Sight flagged some headwinds from both recent and historical reimbursement changes in the MIGS market, notes the firm, which pushed down its 2025 revenue estimate “slightly” as a result. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot |
Sight Sciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSight Sciences ( NASDAQ:SGHT ) Third Quarter 2024 Results Key Financial Results Revenue: US$20.2m (flat on 3Q 2023... |
Sight Sciences Inc (SGHT) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...Sight Sciences Inc (SGHT) reports modest revenue growth and strategic initiatives amid market headwinds in Q3 2024. |
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue EstimatesSight Sciences (SGHT) delivered earnings and revenue surprises of 4.35% and 1.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |